参考文献/References:
[1]中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞 与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南（2021版）[J]. 中华医学杂志,2021,101(1):11-51.
[2]Hoeper MM,Humbert M,Souza R,et al. A global view of pulmonary hypertension[J]. Lancet Respir Med,2016,4(4):306-322.
[3]Chun HJ,Bonnet S,Chan SY. Translational advances in the field of pulmonary hypertension. Translating microRNA biology in pulmonary hypertension. It will take more than “miR” words[J]. Am J Respir Crit Care Med,2017,195(2):167-178.
[4]Daniels LB,Clopton P,Iqbal N,et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients[J]. Am Heart J,2010,160(4):721-728.
[5]Simpson CE,Damico RL,Hassoun PM,et al. Noninvasive prognostic biomarkers for left-sided heart failure as predictors of survival in pulmonary arterial hypertension[J]. Chest,2020,157(6):1606-1616.
[6]Geenen LW,Baggen VJM,Kauling RM,et al. The prognostic value of soluble ST2 in adults with pulmonary hypertension[J]. J Clin Med,2019,8(10):1517.
[7]Ogita M,Miyauchi K,Jiang M,et al. Circulating soluble LR11,a novel marker of smooth muscle cell proliferation,is enhanced after coronary stenting in response to vascular injury[J]. Atherosclerosis,2014,237(1):374-378.
[8]Jiang L,Konishi H,Nurwidya F,et al. Deletion of LR11 attenuates hypoxia-induced pulmonary arterial smooth muscle cell proliferation with medial thickening in mice[J]. Arterioscler Thromb Vasc Biol,2016,36(9):1972-1979.
[9]Kikuchi N,Satoh K,Saito Y,et al. Response by Kikuchi et al Regarding Article, “Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: A Possible Novel Therapeutic Target”[J]. Circulation,2019,139(5):724-725.
[10]Kikuchi N,Satoh K,Satoh T,et al. Diagnostic and prognostic significance of serum levels of SeP(selenoprotein P) in patients with pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol,2019,39(12):2553-2562.
[11]Sun Q,Hackler J,Hilger J,et al. Selenium and copper as biomarkers for pulmonary arterial hypertension in systemic sclerosis[J]. Nutrients,2020,12(6):1894.
[12] Drab M,Verkade P,Elger M,et al. Loss of caveolae,vascular dysfunction,and pulmonary defects in caveolin-1 gene-disrupted mice[J]. Science,2001,293(5539):2449-2452.
[13]Jasmin JF,Mercier I,Dupuis J,et al. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy[J]. Circulation,2006,114(9):912-920.
[14]Zhao YY,Zhao YD,Mirza MK,et al. Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration[J]. J Clin Invest,2009,119(7):2009-2018.
[15]Wang KY,Lee MF,Ho HC,et al. Serum caveolin-1 as a novel biomarker in idiopathic pulmonary artery hypertension[J]. Biomed Res Int,2015,2015:173970.
[16]Sarrion I,Milian L,Juan G,et al. Role of circulating miRNAs as biomarkers in idiopathic pulmonary arterial hypertension:possible relevance of miR-23a[J]. Oxid Med Cell Longev,2015,2015:792846.
[17]Santos-Ferreira CA,Abreu MT,Marques CI,et al. Micro-RNA analysis in pulmonary arterial hypertension:current knowledge and challenges[J]. JACC Basic Transl Sci,2020,5(11):1149-1162.
[18]Luo Y,Dong HY,Zhang B,et al. miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation[J]. Hypertension,2015,65(2):414-420.
[19]Wang T,Li Y,Chen J,et al. TGF-β1/Smad3 signaling promotes collagen synthesis in pulmonary artery smooth muscle by down-regulating miR-29b[J]. Int J Clin Exp Pathol,2018,11(12):5592-5601.
[20]Chen X,Talati M,Fessel JP,et al. Estrogen metabolite 16α-hydroxyestrone exacerbates bone morphogenetic protein receptor type Ⅱ-associated pulmonary arterial hypertension through microRNA-29-mediated modulation of cellular metabolism[J]. Circulation,2016,133(1):82-97.
[21]Wang D,Zhang H,Li M,et al. MicroRNA-124 controls the proliferative,migratory,and inflammatory phenotype of pulmonary vascular fibroblasts[J]. Circ Res,2014,114(1):67-78.
[22]Zhang H,Wang D,Li M,et al. Metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a microRNA-124/PTBP1(polypyrimidine tract binding protein 1)/pyruvate kinase muscle axis[J]. Circulation,2017,136(25):2468-2485.
[23]Caruso P,Dunmore BJ,Schlosser K,et al. Identification of microRNA-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1(polypyrimidine tract binding protein) and pyruvate kinase M2[J]. Circulation,2017,136(25):2451-2467.
[24]Kang K,Peng X,Zhang X,et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells[J]. J Biol Chem,2013,288(35):25414-25427.
[25]Zhu TT,Zhang WF,Yin YL,et al. MicroRNA-140-5p targeting tumor necrosis factor-α prevents pulmonary arterial hypertension[J]. J Cell Physiol,2019,234(6):9535-9550.
[26]Zhang Y,Xu J. MiR-140-5p regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation,apoptosis and differentiation by targeting Dnmt1 and promoting SOD2 expression[J]. Biochem Biophys Res Commun,2016,473(1):342-348.
[27]Rothman AM,Arnold ND,Pickworth JA,et al. MicroRNA-140-5p and SMURF1 regulate pulmonary arterial hypertension[J]. J Clin Invest,2016,126(7):2495-2508.
[28]Zhou G,Chen T,Raj JU.MicroRNAs in pulmonary arterial hypertension[J]. Am J Respir Cell Mol Biol,2015,52(2):139-151.
[29]Courboulin A,Paulin R,Giguère NJ,et al. Role for miR-204 in human pulmonary arterial hypertension[J]. J Exp Med,2011,208(3):535-548.
[30]Meloche J,Pflieger A,Vaillancourt M,et al. Role for DNA damage signaling in pulmonary arterial hypertension[J]. Circulation,2014,129(7):786-797.
[31]Ruffenach G,Chabot S,Tanguay VF,et al. Role for Runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2016,194(10):1273-1285.
[32]Soubrier F,Chung WK,Machado R,et al. Genetics and genomics of pulmonary arterial hypertension[J]. J Am Coll Cardiol,2013,62(25 suppl):D13-D21.
[33]Morrell NW,Aldred MA,Chung WK,et al. Genetics and genomics of pulmonary arterial hypertension[J]. Eur Respir J,2019,53(1):1801899.
[34]Southgate L,Machado RD,Gr?f S,et al. Molecular genetic framework underlying pulmonary arterial hypertension[J]. Nat Rev Cardiol,2020,17(2):85-95.
[35]Rhodes CJ,Batai K,Bleda M,et al. Genetic determinants of risk in pulmonary arterial hypertension:international genome-wide association studies and meta-analysis[J]. Lancet Respir Med,2019,7(3):227-238.
[36]Gr?f S,Haimel M,Bleda M,et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension[J]. Nat Commun,2018,9(1):1416.
[37]Zhu N,Pauciulo MW,Welch CL,et al. Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension[J]. Genome Med,2019,11(1):69.
[38]Ventetuolo CE,Mitra N,Wan F,et al. Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function[J]. Eur Respir J,2016,47(2):553-563.
[39]Damico R,Kolb TM,Valera L,et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension[J]. Am J Respir Crit Care Med,2015,191(2):208-218.
[40]Eyries M,Montani D,Girerd B,et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease,a recessive form of pulmonary hypertension[J]. Nat Genet,2014,46(1):65-69.
[41]Liu D,Liu QQ,Eyries M,et al. Molecular genetics and clinical features of Chinese idiopathic and heritable pulmonary arterial hypertension patients[J]. Eur Respir J,2012,39(3):597-603.
[42]Evans JD,Girerd B,Montani D,et al. BMPR2 mutations and survival in pulmonary arterial hypertension:an individual participant data meta-analysis[J]. Lancet Respir Med,2016,4(2):129-137.
[43]Zhu N,Gonzaga-Jauregui C,Welch CL,et al. Exome sequencing in children with pulmonary arterial hypertension demonstrates differences compared with adults[J]. Circ Genom Precis Med,2018,11(4):e001887.
[44]Germain M,Eyries M,Montani D,et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension[J]. Nat Genet,2013,45(5):518-521.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(11):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(11):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[3]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(11):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[4]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(11):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[5]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[6]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(11):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[7]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(11):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[8]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(11):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[9]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(11):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[10]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(11):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]